Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor.
We characterized the pharmacological properties of the anandamide transport inhibitor N-(4-hydroxyphenyl)-arachidonamide (AM404) in rats and investigated the effects of this drug on behavioral responses associated with activation of dopamine D(2) family receptors. Rat brain slices accumulated [(3)H]anandamide via a high-affinity transport mechanism that was blocked by AM404. When administered alone in vivo, AM404 caused a mild and slow-developing hypokinesia that was significant 60 min after intracerebroventricular injection of the drug and was reversed by the CB1 cannabinoid receptor antagonist SR141716A. AM404 produced no significant catalepsy or analgesia, two typical effects of direct-acting cannabinoid agonists. However, AM404 prevented the stereotypic yawning produced by systemic administration of a low dose of apomorphine, an effect that was dose-dependent and blocked by SR141716A. Furthermore, AM404 reduced the stimulation of motor behaviors elicited by the selective D(2) family receptor agonist quinpirole. Finally, AM404 reduced hyperactivity in juvenile spontaneously hypertensive rats, a putative model of attention deficit hyperactivity disorder. The results support a primary role of the endocannabinoid system in the regulation of psychomotor activity and point to anandamide transport as a potential target for neuropsychiatric medicines.
Beltramo
M
M
The Neurosciences Institute, San Diego, CA 92121, USA.
de Fonseca
F R
FR
Navarro
M
M
Calignano
A
A
Gorriti
M A
MA
Grammatikopoulos
G
G
Sadile
A G
AG
Giuffrida
A
A
Piomelli
D
D
D000818:Animals; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002352:Carrier Proteins / Q000187:drug effects / Q000378:metabolism; D018491:Dopamine Agonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D063388:Endocannabinoids; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D053284:Polyunsaturated Alkamides; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D011955:Receptors, Drug / Q000037:antagonists & inhibitors
D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D002352:Carrier Proteins; D018491:Dopamine Agonists; D065127:Dopamine D2 Receptor Antagonists; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D017448:Receptors, Dopamine D2; D011955:Receptors, Drug; C078814:anandamide; C107594:N-(4-hydroxyphenyl)arachidonylamide